Equities

Zhejiang Shouxiangu Pharmaceutical Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Zhejiang Shouxiangu Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)20.68
  • Today's Change-0.05 / -0.24%
  • Shares traded1.42m
  • 1 Year change+1.97%
  • Beta0.9215
Data delayed at least 15 minutes, as of Feb 13 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Zhejiang Shouxiangu Pharmaceutical Co Ltd is a China-based company principally engaged in the breeding, cultivation, processing and sales of traditional Chinese medicinal materials, such as the ganoderma lucidums and dendrobium officinales. The Company's main products include ganoderma lucidum spore powder, Tiepi Fengdou granule, ganoderma extract products and fresh dendrobium officinales, among others. The Company mainly operates its businesses in domestic markets through wholesaling and direct sales.

  • Revenue in CNY (TTM)649.78m
  • Net income in CNY132.39m
  • Incorporated1997
  • Employees1.12k
  • Location
    Zhejiang Shouxiangu Pharmaceutical Co LtdNo. 12 Huanglong 3rd Road, Wuyi CountyJINHUA 321200ChinaCHN
  • Phone+86 57 987622285
  • Fax+86 57 987621769
  • Websitehttps://www.sxg1909.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Henan Taloph Pharmaceutical Stock Co Ltd1.79bn46.95m3.83bn2.21k75.582.41--2.140.08840.08843.312.780.47912.741.60807,429.601.450.32413.130.610523.4526.223.020.63310.90381.860.359252.82-6.218.1616.002.61-19.14--
Shanghai Shen Lian Biomedical Corp292.81m-30.34m3.97bn391.00--2.81--13.55-0.0739-0.07390.7133.430.18641.420.9144748,865.90-2.213.53-2.403.8057.3673.49-11.8716.933.64--0.010643.520.63943.63-241.95---3.99--
Zhejiang Shouxiangu Pharmaceuticl Co Ltd649.78m132.39m4.10bn1.12k30.961.77--6.310.6680.6683.3011.660.20930.62228.34581,201.904.268.884.8610.3578.2983.0120.3728.553.19--0.198445.94-11.814.81-31.347.1240.840.3458
Shanghai MicuRx Pharmaceutical Co Ltd136.70m-342.96m4.12bn188.00--15.99--30.15-0.5197-0.51970.20770.39290.1610.46613.95727,105.00-40.40-31.40-53.04-35.4184.2682.42-250.89-503.672.15-406.300.5862--43.51---4.65--51.72--
Data as of Feb 13 2026. Currency figures normalised to Zhejiang Shouxiangu Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

2.49%Per cent of shares held by top holders
HolderShares% Held
Orient Securities Asset Management Co. Ltd.as of 30 Jun 20252.00m1.01%
Rongtong Fund Management Co., Ltd.as of 30 Jun 20251.42m0.72%
China Universal Asset Management Co., Ltd.as of 30 Jun 2025589.40k0.30%
Hwabao WP Fund Management Co., Ltd.as of 30 Jun 2025508.20k0.26%
Dimensional Fund Advisors LPas of 08 Jan 2026153.00k0.08%
China Life AMP Asset Management Co., Ltd.as of 30 Jun 2025103.80k0.05%
Broad Fund Management Co. Ltd.as of 30 Jun 202551.60k0.03%
Xingyin Fund Management Co., Ltd.as of 30 Jun 202546.20k0.02%
Great Wall Fund Management Co., Ltd.as of 30 Jun 202525.20k0.01%
China Southern Asset Management Co., Ltd.as of 30 Jun 202511.70k0.01%
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.